These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38320527)

  • 1. A Randomized Trial of Nafamostat for Covid-19.
    Morpeth SC; Venkatesh B; Totterdell JA; McPhee GM; Mahar RK; Jones M; Bandara M; Barina LA; Basnet BK; Bowen AC; Burke AJ; Cochrane B; Denholm JT; Dhungana A; Dore GJ; Dotel R; Duffy E; Dummer J; Foo H; Gilbey TL; Hammond NE; Hudson BJ; Jha V; Jevaji PR; John O; Joshi R; Kang G; Kaur B; Kim S; Das SK; Lau JSY; Littleford R; Marsh JA; Marschner IC; Matthews G; Maze MJ; McArthur CJ; McFadyen JD; McMahon JH; McQuilten ZK; Molton J; Mora JM; Mudaliar V; Nguyen V; O'Sullivan MVN; Pant S; Park JE; Paterson DL; Price DJ; Raymond N; Rees MA; Robinson JO; Rogers BA; Ryu WS; Sasadeusz J; Shum O; Snelling TL; Sommerville C; Trask N; Lewin SR; Hills TE; Davis JS; Roberts JA; Tong SYC
    NEJM Evid; 2023 Nov; 2(11):EVIDoa2300132. PubMed ID: 38320527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.
    Hernández-Mitre MP; Morpeth SC; Venkatesh B; Hills TE; Davis J; Mahar RK; McPhee G; Jones M; Totterdell J; Tong SYC; Roberts JA
    Clin Microbiol Infect; 2024 Jun; 30(6):743-754. PubMed ID: 38331253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics.
    Quinn TM; Gaughan EE; Bruce A; Antonelli J; O'Connor R; Li F; McNamara S; Koch O; MacKintosh C; Dockrell D; Walsh T; Blyth KG; Church C; Schwarze J; Boz C; Valanciute A; Burgess M; Emanuel P; Mills B; Rinaldi G; Hardisty G; Mills R; Findlay EG; Jabbal S; Duncan A; Plant S; Marshall ADL; Young I; Russell K; Scholefield E; Nimmo AF; Nazarov IB; Churchill GC; McCullagh JSO; Ebrahimi KH; Ferrett C; Templeton K; Rannard S; Owen A; Moore A; Finlayson K; Shankar-Hari M; Norrie J; Parker RA; Akram AR; Anthony DC; Dear JW; Hirani N; Dhaliwal K
    EBioMedicine; 2022 Feb; 76():103856. PubMed ID: 35152152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness and Safety of Nafamostat Mesylate in the Treatment of COVID-19: a Meta-Analysis.
    Wei M; Li T; Liu S; Wang Y; Tran C; Ao G
    Jpn J Infect Dis; 2024 May; 77(3):182-186. PubMed ID: 38296543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19.
    McQuilten ZK; Venkatesh B; Jha V; Roberts J; Morpeth SC; Totterdell JA; McPhee GM; Abraham J; Bam N; Bandara M; Bangi AK; Barina LA; Basnet BK; Bhally H; Bhusal KR; Bogati U; Bowen AC; Burke AJ; Christopher DJ; Chunilal SD; Cochrane B; Curnow JL; Das SK; Dhungana A; Di Tanna GL; Dotel R; DSouza H; Dummer J; Dutta S; Foo H; Gilbey TL; Giles ML; Goli K; Gordon A; Gyanwali P; Haksar D; Hudson BJ; Jani MK; Jevaji PR; Jhawar S; Jindal A; John MJ; John M; John FB; John O; Jones M; Joshi RD; Kamath P; Kang G; Karki AR; Karmalkar AM; Kaur B; Koganti KC; Koshy JM; Krishnamurthy MS; Lau JS; Lewin SR; Lim LL; Marschner IC; Marsh JA; Maze MJ; McGree JM; McMahon JH; Medcalf RL; Merriman EG; Misal AP; Mora JM; Mudaliar VK; Nguyen V; O'Sullivan MV; Pant S; Pant P; Paterson DL; Price DJ; Rees MA; Robinson JO; Rogers BA; Samuel S; Sasadeusz J; Sharma D; Sharma PK; Shrestha R; Shrestha SK; Shrestha P; Shukla U; Shum O; Sommerville C; Spelman T; Sullivan RP; Thatavarthi U; Tran HA; Trask N; Whitehead CL; Mahar RK; Hammond NE; McFadyen JD; Snelling TL; Davis JS; Denholm JT; Tong SYC
    NEJM Evid; 2023 Feb; 2(2):EVIDoa2200293. PubMed ID: 38320033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study.
    Soma T; Fujii K; Yoshifuji A; Maruki T; Itoh K; Taniyama D; Kikuchi T; Hasegawa N; Nakamura M
    Jpn J Infect Dis; 2022 Sep; 75(5):484-489. PubMed ID: 35491224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
    Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
    Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
    JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
    Hernández-Mitre MP; Tong SYC; Denholm JT; Dore GJ; Bowen AC; Lewin SR; Venkatesh B; Hills TE; McQuilten Z; Paterson DL; Morpeth SC; Roberts JA
    Clin Pharmacokinet; 2022 Oct; 61(10):1331-1343. PubMed ID: 36040613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
    Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial.
    Berger JS; Neal MD; Kornblith LZ; Gong MN; Reynolds HR; Cushman M; Althouse AD; Lawler PR; McVerry BJ; Kim KS; Baumann Kreuziger L; Solomon SD; Kosiborod MN; Berry SM; Bochicchio GV; Contoli M; Farkouh ME; Froess JD; Gandotra S; Greenstein Y; Hade EM; Hanna N; Hudock K; Hyzy RC; Ibáñez Estéllez F; Iovine N; Khanna AK; Khatri P; Kirwan BA; Kutcher ME; Leifer E; Lim G; Lopes RD; Lopez-Sendon JL; Luther JF; Nigro Maia L; Quigley JG; Wahid L; Wilson JG; Zarychanski R; Kindzelski A; Geraci MW; Hochman JS;
    JAMA Netw Open; 2023 May; 6(5):e2314428. PubMed ID: 37227729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
    Berger JS; Kornblith LZ; Gong MN; Reynolds HR; Cushman M; Cheng Y; McVerry BJ; Kim KS; Lopes RD; Atassi B; Berry S; Bochicchio G; de Oliveira Antunes M; Farkouh ME; Greenstein Y; Hade EM; Hudock K; Hyzy R; Khatri P; Kindzelski A; Kirwan BA; Baumann Kreuziger L; Lawler PR; Leifer E; Lopez-Sendon Moreno J; Lopez-Sendon J; Luther JF; Nigro Maia L; Quigley J; Sherwin R; Wahid L; Wilson J; Hochman JS; Neal MD;
    JAMA; 2022 Jan; 327(3):227-236. PubMed ID: 35040887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial.
    Zhuravel SV; Khmelnitskiy OK; Burlaka OO; Gritsan AI; Goloshchekin BM; Kim S; Hong KY
    EClinicalMedicine; 2021 Nov; 41():101169. PubMed ID: 34723164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial.
    Moon K; Hong KW; Bae IG
    Trials; 2021 Nov; 22(1):832. PubMed ID: 34814935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.